ABSTRACr Isocapnic hyperventilation dose response curves were constructed for 11 asthmatic children before and after pretreatment with placebo or ipratropium bromide, 40-1500 ,g given by inhalation, on three separate days. The response before and after placebo was highly reproducible (within subject coefficient of variation 7.5%, 18%, and 22% for intervals of two hours, within two weeks, and over two weeks). It was independent of baseline lung function. Complete protection against hyperventilation induced asthma was achieved by ipratropium bromide 40 ,ug in six children and by 200 ug or more in a further four. The remaining child was unaffected by any dose of ipratropium up to 1500 ,ug. The dose of ipratropium required for protection was better related to the subjects' requirement for regular medication than to their sensitivity to hyperventilation or baseline lung function.
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For over a decade exercise induced asthma has been a model of asthma by which the protective effect of drugs has been assessed in the laboratory. A single arbitrary level of exercise has often been used, coupled with a single dose of the drug under investigation. Moreover, in a group of asthmatic patients both baseline lung function and the level of bronchial responsiveness may vary widely, so not surprisingly the protection afforded by pretreatment with drugs has often seemed variable and the results conflicting. ' All of these factors need to be taken into account to give useful information about the protective effect of drugs in laboratory models of acute asthma.
Deal and coworkers2 suggested that airway cooling produced by the increase in minute ventilation was the stimulus for exercise induced asthma and recently hyperventilation has been used to assess airway responsiveness in asthmatic subjects. This permits a more easily controlled challenge in which the stimulus can be increased in a stepwise fashion, so that a dose-response relationship between minute ventilation (VE) and airways obstruction can be demonstrated. 3 The role of cholinergic mechanisms in exercise induced asthma is controversial,'45 partly because of the limitations of single dose studies. Recently, Sheppard et a16 have suggested that the greater the bronchoconstrictor stimulus the greater the dose of anticholinergic drug (in their case atropine) that is required to provide protection. Most studies with anticholinergic drugs have been performed in adults with relatively mild asthma and the additional importance of variations in reactivity between individuals has not been adequately studied.
The aims of this study were, firstly, to look at the reproducibility of hyperventilation dose-response tests in asthmatic children with a wide spectrum of sensitivity to hyperventilation and, secondly, to investigate the effect of pretreatment with ipratropium bromide on hyperventilation induced asthma.
Methods
Seven boys and four girls with a history of exercise induced asthma were selected for the study (table  1) . A wide range of severity of clinical asthma was represented in this group. Inhaled steroids and ,3 agonists were discontinued for 12 hours and sus-588 Results were analysed with both actual PD20 and " normalised" PD20, obtained by dividing by the predicted FEV,.
Results

REPRODUCIBILITY OF HYPERVENTILATION PD20
On the placebo study day two hyperventilation tests were performed with a two hour interval (fig 2) . The mean values of PD20 for the two tests were close and the within subject coefficient of variation was 7.5% (95% confidence limit ±+15%). The within subject coefficient of variation increased as the test interval increased-to 18% for separate days within two weeks and 22% for an interval of over two weeks. The within subject coefficient of variation of The effect of pretreatment of ipratropium bromide 200 ,g was studied in all the children (table 2) .
There was a 20% mean rise in baseline FEV, after ipratropium, from a mean (SD) of 65% (17%) to 78% (18%) of the predicted value.'0 A significant rise also occurred after placebo, from 70% (18 %) to 74% (16%) predicted (p < 0.01) but this represented only a 6% mean rise.
Nine of the 11 subjects (nos 1-9) were protected by ipratropium bromide 200 ,ug. In these children there was a fall in FEV, after hyperventilation of less than 10% despite a 27% increase in the mean (SD) level of the hyperventilation stimulus to 37 (5.2) 1 min-', compared with the maximum control VE of 27 (6.5) 1 min-'. Six children (1-6) were found to be protected by ipratropium 40 ,ug and in the remaining three (7-9) there was some shift in the dose-response curve after 40 ,ug but the addition of a further 80 ,ug, giving an approximate total of 120 ug, did not afford any greater protection (table  2) .
The two children (10 and 11) who were not protected by pretreatment with ipratropium bromide 200 ug were tested with the higher concentrations.
Subject 10 showed a progressive shift in his doseresponse curve as the concentration of ipratropium was increased from 200 to 500 ug, with complete protection after 1500 pmg (fig 4) . The most sensitive subject, No 11, failed to show any protection from hyperventilation induced asthma at any dose used. No significant correlation was found between sensitivity to hyperventilation (PD20) and the dose of ipratropium bromide required to afford complete protection. The usual treatment being taken by the children was significantly associated with the dose of ipratropium required for protection. Of the six children protected by ipratropium 40 ,ug, five were taking intermittent bronchidilators only; of the children requiring 200 pg or more, all required regular prophylactic treatment (Fisher's exact test, p < 0 02).
Discussion
Isocapnic hyperventilation challenge tests were easily performed in our group of 11 children, and provided reproducible values of PD20. The degree of reproducibility of the PD20, calculated from tests performed with a two hour interval (coefficient of variation 7-5 %), makes the test useful for assessing the protective effect of drugs. The reproducibility compares favourably with that of histamine inhalation challenge,"' which has been successfully used as a sensitive means of detecting changes in bronchial responsiveness. '2 13 The between test (table 2) . It was considered wise to perform a pair of tests with at least a two hour interval between them, as refractoriness has been found to occur in some children after hyperventilation induced asthma."5 1" Refractoriness could have had a flattening effect on individual dose-response curves, but this did not interfere with the reproducibility of the test.
We found considerable intersubject difference in the dose of ipratropium bromide required to blunt or abolish the fall in FEVy after hyperventilation. Six children were completely protected by 40 ,mg but four required 200-1500 ,ug and one was unaffected by 1500 ,ug. We do not know whether a higher dose would have protected this latter child, although even at this dose there were no ill effects and no change in pulse rate. The reproducibility of the protective effect of ipratropium has never been assessed. In a study'5 looking at the effect of ipratropium on single dose hyperventilation challenge we found 11 of 19 subjects were completely protected by ipratropium bromide 80 ug, and it was suggested that a cholinergic mechanism was important only in those subjects whom we were unable to make refractory by repeated challenges. Further work is needed to see whether those subjects requiring higher doses of ipratropium to prevent hyperventilation induced asthma are more refractory to repeated hyperventilation than those protected by lower doses.
Protection by a bronchodilator drug against induced asthma could be explained by an increase in airway calibre. The measurement of FEV, (or any other parameter of airflow) is only an approximate and indirect measure of airway calibre. We found no evidence, however, that changes in baseline FEV, were associated with changes in PD20 (fig 3) . Spontaneous changes in FEV, before control tests on two separate test days (table 2) had no effect on PD20, whereas after ipratropium bromide 200 ,ug similar changes in FEV1 were associated with a considerable and highly significant increase in PD20 (fig 5) . The mean PD20 value after ipratropium bromide 200 ,ug was in fact an underestimate, since nine out of 11 children were completely protected (that is, achieved their maximum VE without a fall in FEV,); so the maximum VE achieved was used in place of the PD20 for these children. Thus only a small part of the protection against hyperventilation induced asthma afforded by ipratropium bromide was Bronchial responsiveness to hyperventilation in children with asthma: inhibition by ipratropium bromide593 could be dangerous for patients as severely affected as ours.
By the use of hyperventilation dose-response challenge tests and of varying doses of ipratropium bromide, we have shown a range of responsiveness of asthmatic children to the drug, which was independent of the severity of hyperventilation induced asthma and of the bronchodilator action of ipratropium, but which did related to the overall clinical severity of asthma. A "standard" dose for all asthmatic children is clearly inappropriate. Moreover, a dose which produces effective bronchodilatation may be quite inadequate to protect against a powerful provoking stimulus, just as a dose failing to produce bronchodilatation may protect fully. Much higher single doses of ipratropium bromide than are normally recommended may be given to individual patients with particularly intractible asthma and in this study they produced no side effects.
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